the N-oxide forms, the pharmaceutically acceptable addition salts and the
stereochemically isomeric forms thereof, wherein n is 0, 1 or 2;
R.sup.2 represents hydroxy; --X-- represents C.sub.2-4alkynyl,
C.sub.1-12alkyl optionally substituted with hydroxy or X represents a
divalent radical of the formula wherein; --X.sub.1-- represents
C.sub.1-12alkyl, phenyl or a divalent radical selected from the group
consisting of --X.sub.2-- represents C.sub.1-12alkyl,
C.sub.1-4alkyloxyC.sub.1-4alkyl, phenyl or a divalent radical of formula
--X.sub.3-- represents phenyl or a divalent radical selected from the
group consisting of R.sup.1 independently represents hydrogen,
C.sub.1-4alkyl, C.sub.1-4alkyloxy-, Ar.sup.1, Ar.sup.2-carbonyl,
Het.sup.1-C.sub.1-4alkyl, Het.sup.2, NR.sup.3R.sup.4--C.sub.1-4alkyl,
Ar.sup.3-C.sub.1-4alkyloxy- or Het.sup.4-oxy-; R.sup.3 and R.sup.4 each
independently represents hydrogen, C.sub.1-4alkyl, C.sub.1-4alkyloxy-, or
Het.sup.3; Het.sup.1 represents a heterocycle selected from pyridinyl,
indolinyl, indolyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl,
thiazolyl, pyridinyl, or thiadiazolyl wherein said Het.sup.1 is
optionally substituted with one or where possible two or more
substituents selected from the group consisting of hydroxy, halo,
C.sub.1-4alkyloxycarbonyl-, C.sub.1-4alkyl-, C.sub.1-4alkyloxy- and
C.sub.1-4alkyloxy-substituted with halo; in particular Het.sup.1
represents a heterocycle selected from indolyl or pyridinyl; Het.sup.2
represents a heterocycle selected from indolyl, benzisoxazolyl or
oxodiazolyl wherein said Het.sup.2 is optionally substituted with one or
where possible two or more substituents selected from the group
consisting of hydroxy, halo, C.sub.1-6alkyl- and C.sub.1-4alkyloxy-;
Het.sup.3 represents a heterocycle selected from benzimidazolyl,
benzisoxazolyl or benzthiazolyl wherein said Het.sup.3 is optionally
substituted with one or where possible two or more substituents selected
from the group consisting of hydroxy, halo, C.sub.1-6alkyl- and
C.sub.1-4alkyloxy-; in particular Het.sup.3 represents benzthiazolyl
substituted with C.sub.1-4alkyloxy-; Het.sup.4 represents a heterocycle
selected from benzimidazolyl, benzisoxazolyl or benzthiazolyl wherein
said Het.sup.4 is optionally substituted with one or where possible two
or more substituents selected from the group consisting of hydroxy, halo,
C.sub.1-6alkyl- and C.sub.1-4alkyloxy-; in particular Het.sup.4
represents benzthiazolyl; Ar.sup.1 represents phenyl optionally
substituted with halo, C.sub.1-4alkyl or C.sub.1-4alkyl substituted with
one, two or three halo substituents; Ar.sup.2 represents phenyl
optionally substituted with halo, C.sub.1-4alkyl or C.sub.1-4alkyl
substituted with one, two or three halo substituents; in particular
Ar.sup.2 represents phenyl substituted with halo or trifluromethyl;
Ar.sup.3 represents phenyl optionally substituted with halo,
C.sub.1-4alkyl or C.sub.1-4alkyloxy-.